California voters have approved Proposition 38, authorising the state to borrow $8.4 billion for immunology and medical research, one of the largest voter-approved science bonds in American history. The Associated Press called the race late on Monday, November 9, 2026, six days after the November 3 midterm election, with the measure leading by about 56 percent to 44 percent.

The bond will fund research aimed at curing and preventing chronic diseases, with at least $4.2 billion earmarked for immunology research into cancer, heart disease and Alzheimer's disease. Half goes to one institute chosen by the California Department of Public Health; the rest funds competitive grants. Repayment is estimated at $500 million to $600 million a year for about 20 years, roughly $12 billion with interest.

Key Points

• California voters approved Proposition 38 on November 3, 2026; the Associated Press called it late on November 9, with the measure leading about 56 percent to 44 percent.
• The measure authorises $8.4 billion in general obligation bonds for immunology and immunotherapy research aimed at curing and preventing chronic diseases.
• At least $4.2 billion is earmarked for immunology research on cancer, heart disease and Alzheimer's disease.
• About $4.2 billion goes to one unnamed institute chosen by the California Department of Public Health; CalMatters reported only one organisation qualifies, the UCLA-affiliated California Institute for Immunology and Immunotherapy.
• Repayment is estimated at $500 million to $600 million a year for about 20 years, roughly $12 billion with interest; results are certified on December 11.

What Happened

Proposition 38 was on the ballot on November 3, 2026, and counting continued for six days before the Associated Press called the race late on Monday, November 9. The measure led by about 56 percent to 44 percent, a margin leaving little doubt about the result. The late call reflected the scale of California's vote count, not a close contest: the state counts millions of mail ballots after Election Day.

Proposition 38 was written and chiefly funded by billionaire surgeon Gary K. Michelson, who also backed the California Institute for Immunology and Immunotherapy, the UCLA-affiliated institute CalMatters reported is currently the only organisation meeting the measure's criteria. On the same day, voters rejected Proposition 40, the one-time tax on billionaires, by 52.8 percent to 47.2 percent. The contrast shows voters were willing to approve large new public spending on medical research while rejecting a new tax on the state's wealthiest residents to pay for health care.

Background and Context

In 2004, voters approved Proposition 71, authorising $3 billion in bonds for stem-cell research and creating the California Institute for Regenerative Medicine; in 2020, Proposition 14 added $5.5 billion more. Together they committed $8.5 billion to stem-cell science, a sum Proposition 38 nearly matches on its own. The new measure shifts the focus to immunology and immunotherapy, the study of how the immune system can be trained to fight disease. Immunotherapy has already transformed some cancer treatments, and researchers believe it could eventually help prevent or treat heart disease, Alzheimer's disease and other chronic conditions that dominate California's health burden.

California Proposition 38: How the $8.4 Billion Will Be Spent

At least $4.2 billion must go to immunology research on cancer, heart disease and Alzheimer's disease. The measure does not name the institute that will receive the single-institute share; instead, the California Department of Public Health will select it using criteria set out in the measure. CalMatters reported that only one organisation currently meets those criteria: the California Institute for Immunology and Immunotherapy, affiliated with UCLA and backed by Michelson.

The remaining $4.2 billion will be distributed through competitive grants awarded by a council of representatives from University of California campuses, other universities and non-profit research institutions. The bonds are general obligation bonds, repaid from the General Fund at an estimated $500 million to $600 million a year for about 20 years.

Reactions

The measure's passage was a victory for Gary K. Michelson, who wrote Proposition 38 and financed the campaign to put it before voters. Michelson, a surgeon and inventor who made his fortune in spinal surgery devices, has long argued that immunology holds the key to cures for the chronic diseases that now kill most Americans. The Legislative Analyst's Office provided the neutral fiscal analysis that framed the debate, putting the cost at $500 million to $600 million a year for about 20 years. CalMatters' reporting added a key detail: only one organisation meets the criteria for the single-institute share, meaning voters effectively approved a large grant to an institute already identifiable, though the measure names no recipient.

Why It Matters

At $8.4 billion, Proposition 38 is one of the largest single investments in medical research ever approved by voters in the United States, committing California to a generation of immunology research as federal science funding faces uncertainty. Directing half of the bond to one institute is also unusual, and the fact that only one organisation currently qualifies means the California Institute for Immunology and Immunotherapy is positioned to become one of the best-funded immunology centres in the world. For patients, the promise is distant but real: immunotherapy has already extended lives in some cancers, and the research could, over a decade or more, produce treatments for heart disease and Alzheimer's disease, which currently have no cure.

What Happens Next

Results will be certified on December 11, after which Proposition 38 becomes law and the state can begin issuing bonds, typically in tranches as the money is needed. The Department of Public Health must then select the institute for the single-institute share, a process likely to be closely watched. The grants council must also be formed before the competitive half of the money can be awarded. Over the longer term, success will be judged by what the research produces: the stem-cell bonds of 2004 and 2020 took years to yield clinical results, and immunology research is likely to follow a similar timeline.

Frequently Asked Questions

What is Proposition 38? A California ballot measure approved on November 3, 2026, authorising $8.4 billion for immunology and immunotherapy research into cancer, heart disease and Alzheimer's disease.

How much will Proposition 38 cost taxpayers? The Legislative Analyst's Office estimates $500 million to $600 million a year for about 20 years from the General Fund, roughly $12 billion with interest.

Who gets the Proposition 38 money? About half, $4.2 billion, goes to one institute chosen by the California Department of Public Health; CalMatters reported only one organisation qualifies, the UCLA-affiliated California Institute for Immunology and Immunotherapy. The rest funds competitive grants.

When will the results be certified? On December 11, 2026. The Associated Press called the race late on November 9, with the measure leading about 56 percent to 44 percent.

How does Proposition 38 compare with California's earlier research bonds? Proposition 71 (2004) authorised $3 billion for stem-cell research and Proposition 14 (2020) added $5.5 billion, $8.5 billion in total, almost exactly Proposition 38's $8.4 billion, but for immunology, not stem cells.

Read more on the California ballot: voters also rejected Proposition 40, the billionaire tax, by 52.8 percent to 47.2 percent, and Xavier Becerra won the California governor's race, becoming the state's first Latino governor in 150 years.